US Bancorp DE Sells 448 Shares of Denali Therapeutics Inc. (NASDAQ:DNLI)

US Bancorp DE cut its stake in shares of Denali Therapeutics Inc. (NASDAQ:DNLI) by 27.7% in the 3rd quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The fund owned 1,168 shares of the company’s stock after selling 448 shares during the quarter. US Bancorp DE’s holdings in Denali Therapeutics were worth $34,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Other large investors have also added to or reduced their stakes in the company. MONECO Advisors LLC increased its stake in shares of Denali Therapeutics by 4.6% in the third quarter. MONECO Advisors LLC now owns 9,100 shares of the company’s stock worth $265,000 after buying an additional 400 shares during the period. CWM LLC lifted its stake in shares of Denali Therapeutics by 43.6% in the third quarter. CWM LLC now owns 2,153 shares of the company’s stock worth $63,000 after buying an additional 654 shares in the last quarter. Mirae Asset Global Investments Co. Ltd. raised its stake in shares of Denali Therapeutics by 21.6% in the third quarter. Mirae Asset Global Investments Co. Ltd. now owns 5,178 shares of the company’s stock worth $152,000 after purchasing an additional 920 shares during the last quarter. Zurcher Kantonalbank Zurich Cantonalbank grew its stake in shares of Denali Therapeutics by 5.5% in the second quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 26,403 shares of the company’s stock worth $613,000 after acquiring an additional 1,372 shares during the period. Finally, Swiss National Bank boosted its stake in shares of Denali Therapeutics by 0.7% in the 1st quarter. Swiss National Bank now owns 218,200 shares of the company’s stock worth $4,477,000 after buying an additional 1,500 shares during the last quarter. Hedge funds and other institutional investors own 92.92% of the company’s stock.

Denali Therapeutics Stock Down 3.5 %

Shares of DNLI stock opened at $24.18 on Tuesday. Denali Therapeutics Inc. has a 52-week low of $14.56 and a 52-week high of $33.33. The stock has a market cap of $3.48 billion, a PE ratio of -8.76 and a beta of 1.40. The business has a 50-day simple moving average of $28.20 and a 200-day simple moving average of $24.09.

Denali Therapeutics (NASDAQ:DNLI) last released its quarterly earnings results on Wednesday, November 6th. The company reported ($0.63) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.60) by ($0.03). During the same period in the prior year, the business earned ($0.72) earnings per share. Sell-side analysts anticipate that Denali Therapeutics Inc. will post -2.69 earnings per share for the current fiscal year.

Wall Street Analysts Forecast Growth

A number of equities analysts recently commented on DNLI shares. Jefferies Financial Group raised their target price on Denali Therapeutics from $40.00 to $45.00 and gave the stock a “buy” rating in a report on Friday, November 1st. Citigroup boosted their target price on Denali Therapeutics from $26.00 to $32.00 and gave the company a “buy” rating in a research report on Friday, August 2nd. Bank of America raised their target price on shares of Denali Therapeutics from $25.00 to $29.00 and gave the stock a “buy” rating in a research report on Wednesday, September 4th. Wedbush reduced their price target on shares of Denali Therapeutics from $30.00 to $26.00 and set an “outperform” rating for the company in a report on Friday, August 2nd. Finally, JPMorgan Chase & Co. decreased their target price on shares of Denali Therapeutics from $29.00 to $28.00 and set an “overweight” rating for the company in a research report on Friday, October 11th. Three research analysts have rated the stock with a hold rating and eight have given a buy rating to the stock. According to MarketBeat.com, Denali Therapeutics has a consensus rating of “Moderate Buy” and a consensus price target of $38.90.

Insiders Place Their Bets

In other Denali Therapeutics news, Director Steve E. Krognes sold 30,000 shares of Denali Therapeutics stock in a transaction on Monday, September 30th. The stock was sold at an average price of $29.03, for a total value of $870,900.00. Following the sale, the director now owns 29,096 shares in the company, valued at $844,656.88. The trade was a 50.76 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. Also, CEO Ryan J. Watts sold 40,000 shares of Denali Therapeutics stock in a transaction dated Friday, October 18th. The shares were sold at an average price of $27.69, for a total transaction of $1,107,600.00. Following the sale, the chief executive officer now owns 235,807 shares of the company’s stock, valued at approximately $6,529,495.83. This represents a 14.50 % decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last three months, insiders sold 86,578 shares of company stock worth $2,474,440. Corporate insiders own 7.90% of the company’s stock.

Denali Therapeutics Company Profile

Denali Therapeutics Inc, a biopharmaceutical company, develops a portfolio of product candidates engineered to cross the blood-brain barrier for neurodegenerative diseases and lysosomal storage diseases in the United States. The company’s transport vehicle (TV)-enabled programs include DNL310 ETV, an IDS enzyme replacement therapy program for MPS II; TAK-594/DNL593 which is in Phase 1/II for frontotemporal dementia-granulin; DNL126 program for MPS IIIA; and DNL622 for MPS I, as well as other preclinical programs that target amyloid beta and HER2.